Literature DB >> 12084309

Oral and injectable medications for the treatment of erectile dysfunction.

C C Carson1.   

Abstract

The treatment of erectile dysfunction has changed dramatically over the past two decades. The introduction of the oral agent sildenafil 2 years ago has revolutionized the treatment of men with compromised erections and has met with expected success and low morbidity. Sildenafil is effective in most men with erectile dysfunction in the general population and in select populations, such as men with spinal cord injury, diabetes mellitus, and patients who have had nerve-sparing radical prostatectomy. It is safe in the general population as well as in many men with cardiac disease. Other newer medications are in trial and may soon be available to supplement treatment with sildenafil. Oral phentolamine, apomorphine, newer phosphodiesterase type-5 inhibitors, and topical agents are currently in phase 3 trials. These agents, in addition to newer intraurethral and indictable agents, may assist men with erectile dysfunction and rescue those in whom sildenafil is ineffective or in whom untoward side effects of sildenafil reduce its effectiveness. The 21st century will witness many additional agents designed for specific patients with specific conditions causing erectile dysfunction. We can expect these oral agents, assisted by topical and injectable agents, to successfully restore erectile function in the majority of men suffering from erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12084309     DOI: 10.1007/s11934-000-0012-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  46 in total

1.  Hypertensive crisis from herbal treatment of impotence.

Authors:  B Ruck; R D Shih; S M Marcus
Journal:  Am J Emerg Med       Date:  1999-05       Impact factor: 2.469

2.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

3.  This month in investigative urology. L-arginine and penile erection.

Authors:  A Melman
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

4.  Priapism associated with trazodone therapy.

Authors:  C C Carson; R D Mino
Journal:  J Urol       Date:  1988-02       Impact factor: 7.450

5.  The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat.

Authors:  K E Andersson; H Gemalmaz; K Waldeck; T N Chapman; J B Tuttle; W D Steers
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

Review 6.  Physiology of penile erection.

Authors:  K E Andersson; G Wagner
Journal:  Physiol Rev       Date:  1995-01       Impact factor: 37.312

7.  Indications and early results of sildenafil (Viagra) in erectile dysfunction.

Authors:  R Virag
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

8.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

Authors:  M S Rendell; J Rajfer; P A Wicker; M D Smith
Journal:  JAMA       Date:  1999-02-03       Impact factor: 56.272

9.  Modulation of vasoactive intestinal polypeptide (VIP)-mediated relaxation by nitric oxide and prostanoids in the rabbit corpus cavernosum.

Authors:  Y C Kim; J H Kim; M G Davies; P O Hagen; C C Carson
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

10.  Effect of yohimbine hydrochloride on erectile impotence: a double-blind study.

Authors:  J G Susset; C D Tessier; J Wincze; S Bansal; C Malhotra; M G Schwacha
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.